Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) has been assigned an average rating of “Moderate Buy” from the seven brokerages that are currently covering the company, Marketbeat reports. Two ...

StockNews.com cut shares of Aclaris Therapeutics (NASDAQ:ACRS – Free Report) from a hold rating to a sell rating in a report ...

Glox Therapeutics has appointed of Michael Murray as chair of its board. He will work with the leadership team to accelerate ...

Hoth Therapeutics Inc., a biopharmaceutical company committed to developing innovative therapies for unmet medical needs, has collaborated with OnTargetx R&D Inc. to accelerate research for its cancer ...

Truist lowered the firm’s price target on Viking Therapeutics (VKTX) to $95 from $120 and keeps a Buy rating on the shares. The company’s Q4 ...

Researchers discovered the importance of an enzyme that promotes growth of certain lung cancers. Lung cancer is a ...

Fintel reports that on February 4, 2025, Wolfe Research initiated coverage of Oruka Therapeutics (NasdaqGM:ORKA) with a Outperform recommendation. Analyst Price Forecast Suggests 210.29% Upside As of ...

Brookline Capital Markets initiated coverage on Marker Therapeutics (NASDAQ:MRKR), a company focused on developing T cell-based immunotherapies for cancer, with a Buy rating and a 12-to-18-month price ...

Citi analyst David Lebowitz initiated coverage of Viking Therapeutics (VKTX) with a Neutral rating and $38 price target Viking’s VK2735 is an ...

Breast cancers at all stages are defined by the structure of their genomes, researchers find. Targeting these processes early is likely to offer unexpected therapeutic avenues.

Mass General Brigham researchers discovered a previously unknown mechanism that may drive tissue damage and a new target for drug discovery ...